Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Merck
Argus Health
McKinsey
Citi
AstraZeneca
Cantor Fitzgerald
Novartis
Daiichi Sankyo
QuintilesIMS

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,844,013

« Back to Dashboard

Which drugs does patent 6,844,013 protect, and when does it expire?

Patent 6,844,013 protects PICATO and is included in one NDA.

This patent has seventeen patent family members in fifteen countries.
Summary for Patent: 6,844,013
Title: Methods of stimulating the immune system
Abstract:This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (St. Lucia, AU)
Assignee: Peplin Research Pty Ltd (Fortitude Valley, AT)
Application Number:09/888,997
Patent Claim Types:
see list of patent claims
Use; Process; Composition;

Drugs Protected by US Patent 6,844,013

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION ➤ Sign Up
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,844,013

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPO 8640Aug 19, 1997

Non-Orange Book US Patents Family Members for Patent 6,844,013

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,452 Anti-cancer compounds ➤ Sign Up
6,787,161 Anti-cancer compounds ➤ Sign Up
7,410,656 Anti-cancer compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,844,013

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 736230 ➤ Sign Up
Brazil 9811327 ➤ Sign Up
Canada 2301082 ➤ Sign Up
China 1266421 ➤ Sign Up
Cyprus 1108303 ➤ Sign Up
Germany 69839586 ➤ Sign Up
Denmark 1015413 ➤ Sign Up
European Patent Office 1015413 ➤ Sign Up C300592 Netherlands ➤ Sign Up
European Patent Office 1015413 ➤ Sign Up CA 2013 00024 Denmark ➤ Sign Up
European Patent Office 1015413 ➤ Sign Up 92185 Luxembourg ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
UBS
Federal Trade Commission
Healthtrust
Teva
Johnson and Johnson
Cipla
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot